• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PRAVASTATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • PRAVASTATIN chembl:CHEMBL1144 Approved

    Alternate Names:

    PRAVACHOL
    PRAVASTATIN
    C10AA03
    (+)-(3R,5R)-3,5-DIHYDROXY-7-[(1S,2S,6S,8S,8AR)-6-HYDROXY-2-METHYL-8-{[(S)-2-METHYLBUTYRYL]OXY}-1,2,6,7,8,8A-HEXAHYDRO-1-NAPHTHYL]HEPTANOIC ACID
    PRAVACHOL®
    PRAVASTATINA
    PRAVASTATIN ACID
    LIPOSTAT®
    PRAVASTATIN SODIUM
    PRAVASTATINE
    PRAVASTATINUM
    chemidplus:81093-37-0
    chembl:CHEMBL1144
    drugbank:00175
    rxcui:42463
    pubchem.compound:54687

    Drug Info:

    Drug Indications anticholesterolaemic agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypecholesterolemic agent
    Drug Class anticholesteremic agents
    Year of Approval 1991
    (2 More Sources)

    Publications:

    Maitland-van der Zee AH et al., 2008, Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study., Pharmacogenet Genomics
    Voora D et al., 2008, Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response., Circ Cardiovasc Genet
    Li J et al., 2009, Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease., Clin Exp Pharmacol Physiol
    Medina MW et al., 2012, RHOA is a modulator of the cholesterol-lowering effects of statin., PLoS Genet
    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    Zheng et al., 2005, [Effects of interaction between vascular endothelial cells and monocytes on expression of matrix metalloproteinase-2 and of tissue inhibitor of metalloproteinases 2 and regulation of pravastatin]., Zhonghua Bing Li Xue Za Zhi
    Boekholdt SM et al., 2003, Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events., Circulation
    Niemi M et al., 2006, Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics., Pharmacogenet Genomics
    Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
    Mega JL et al., 2009, Identification of genetic variants associated with response to statin therapy., Arterioscler Thromb Vasc Biol
    Lahoz C et al., 2005, The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment., Atherosclerosis
    Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
    Shiffman D et al., 2010, Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial., Am J Cardiol
    Iakoubova OA et al., 2010, KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study., Eur J Cardiovasc Prev Rehabil
    Iakoubova OA et al., 2008, Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study., J Am Coll Cardiol
    Iakoubova OA et al., 2008, Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials., J Am Coll Cardiol
    Schmidt et al., Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir., J Am Board Fam Med
    Sai K et al., 2016, A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metab Pharmacokinet
    Bessler et al., 2005, In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells., Clin. Immunol.
    Parhofer et al., 1993, Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia., Clin Investig
    Polisecki E et al., 2010, Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly., J Lipid Res
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
    Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
    Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
    Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
    Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
    Ray SK et al., 2000, Atorvastatin: in the management of hyperlipidaemia., J Postgrad Med
    Ye YC et al., 2015, Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients., Chin Med J (Engl)
    Kuivenhoven JA et al., 1998, The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group., N Engl J Med
    Regieli JJ et al., 2008, CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction., Eur Heart J
    Mohrschladt MF et al., 2005, TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia., Eur J Hum Genet
    Knoblauch H et al., 2004, Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol., Hum Mol Genet
    Carlquist JF et al., 2003, The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease., Am Heart J
    de Maat MP et al., 1999, Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis., Am J Cardiol
    Sabatine MS et al., 2008, Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy., Arterioscler Thromb Vasc Biol
    Demyanets et al., 2006, Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro., Biochem. Pharmacol.
    Igel et al., 2006, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin., Clin. Pharmacol. Ther.
    Ruaño G et al., 2007, Physiogenomic association of statin-related myalgia to serotonin receptors., Muscle Nerve
    Ho et al., 2007, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants., Pharmacogenet. Genomics
    Keskitalo JE et al., 2009, Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin., Pharmacogenomics
    Ledmyr H et al., 2004, The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease., Circulation
    Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
    Lehtimäki T et al., 2003, Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men., Pharmacogenetics
    Verma et al., 2004, Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells., J. Surg. Res.
    Mulder HJ et al., 2003, DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial., Heart
    Marian AJ et al., 2000, Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study., J Am Coll Cardiol
    Bray PF et al., 2001, The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction., Am J Cardiol
  • PRAVASTATIN   ADAMTS1

    Interaction Score: 3.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18174457


    Sources:
    PharmGKB

  • PRAVASTATIN   KIF6

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20403483 20215968 18222355 18222353


    Sources:
    PharmGKB

  • PRAVASTATIN   NPC1L1

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19752398


    Sources:
    PharmGKB

  • PRAVASTATIN   HMGCR

    Interaction Score: 1.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CRES pravastatin
    Novel drug target Established target
    Trial Name pravastatin and fenofibrate,PravaFen

    PMIDs:
    11752352 18815589 18332269 18261733 17563401 16103896 15199031 11298482 25591572


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • PRAVASTATIN   RHOA

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23166513


    Sources:
    PharmGKB

  • PRAVASTATIN   CETP

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9420339 18957472 15856070 15044381 14660992


    Sources:
    PharmGKB

  • PRAVASTATIN   ABCA1

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20031551 19673941


    Sources:
    PharmGKB

  • PRAVASTATIN   LIPC

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16115483 16103896


    Sources:
    PharmGKB

  • PRAVASTATIN   MTTP

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15136504


    Sources:
    PharmGKB

  • PRAVASTATIN   TLR4

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12742999


    Sources:
    PharmGKB

  • PRAVASTATIN   APOE

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19667110 17289397


    Sources:
    PharmGKB

  • PRAVASTATIN   HTR3B

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17600820


    Sources:
    PharmGKB

  • PRAVASTATIN   MMP3

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10190398


    Sources:
    PharmGKB

  • PRAVASTATIN   SLC22A6

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PRAVASTATIN   ABCB11

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PRAVASTATIN   LPL

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896


    Sources:
    PharmGKB

  • PRAVASTATIN   APOB

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8312689


    Sources:
    NCI

  • PRAVASTATIN   SLCO1B3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • PRAVASTATIN   ACE

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896 12695469 10636265 11545752


    Sources:
    PharmGKB

  • PRAVASTATIN   HTR7

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17600820


    Sources:
    PharmGKB

  • PRAVASTATIN   SLC22A8

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PRAVASTATIN   MMP2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15842807


    Sources:
    NCI

  • PRAVASTATIN   MTHFR

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18622257


    Sources:
    PharmGKB

  • PRAVASTATIN   ABCG2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17622941 19842935


    Sources:
    NCI PharmGKB

  • PRAVASTATIN   HLA-DRB1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27839692


    Sources:
    PharmGKB

  • PRAVASTATIN   IL2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16051523


    Sources:
    NCI

  • PRAVASTATIN   SLCO2B1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PRAVASTATIN   IL1B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14515062


    Sources:
    PharmGKB

  • PRAVASTATIN   NOS1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15126084


    Sources:
    NCI

  • PRAVASTATIN   LDLR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PRAVASTATIN   BAX

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16540096


    Sources:
    NCI

  • PRAVASTATIN   SLCO1B1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16678544


    Sources:
    NCI

  • PRAVASTATIN   ABCC2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17047488


    Sources:
    PharmGKB

  • PRAVASTATIN   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15616150 19667110


    Sources:
    NCI PharmGKB

  • PRAVASTATIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17615423


    Sources:
    NCI

  • TEND: PRAVASTATIN

    • Version: 01-August-2011

    Alternate Names:
    PRAVASTATIN Primary Drug Name

    Drug Info:
    Year of Approval 1991
    Drug Class anticholesteremic agents

    Publications:

  • TdgClinicalTrial: PRAVASTATIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypecholesterolemic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: PRAVASTATIN

    • Version: 14-September-2017

    Alternate Names:
    C29375 NCI drug code

    Drug Info:

    Publications:
    Igel et al., 2006, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin., Clin. Pharmacol. Ther.
    Verma et al., 2004, Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells., J. Surg. Res.
    Bessler et al., 2005, In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells., Clin. Immunol.

  • PharmGKB: pravastatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Maitland-van der Zee AH et al., 2008, Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study., Pharmacogenet Genomics
    Shiffman D et al., 2010, Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial., Am J Cardiol
    Iakoubova OA et al., 2008, Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials., J Am Coll Cardiol

  • TTD: Pravastatin

    • Version: 2020.06.01

    Alternate Names:
    D02RQU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1144

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21